- PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference
- Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic Hyperplasia
- PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
- Late Breaking Abstract Presented at the Japanese Urological Association Annual Meeting on Aquablation Therapy Outcomes for Men in Japan with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
- PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting
- PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas
- PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024
- PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results
- PROCEPT BioRobotics to Present at the 44th Annual TD Cowen Health Care Conference in Boston
- PROCEPT BioRobotics® Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 million
More ▼
Key statistics
As of last trade Procept Biorobotics Corp (PRCT:NMQ) traded at 68.47, -11.08% below its 52-week high of 77.00, set on May 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 68.33 |
---|---|
High | 68.99 |
Low | 68.24 |
Bid | 68.37 |
Offer | 68.56 |
Previous close | 68.70 |
Average volume | 543.45k |
---|---|
Shares outstanding | 51.42m |
Free float | 49.13m |
P/E (TTM) | -- |
Market cap | 3.53bn USD |
EPS (TTM) | -2.12 USD |
Data delayed at least 15 minutes, as of May 21 2024 16:57 BST.
More ▼